Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,141,969
  • Shares Outstanding, K 86,974
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,180 K
  • 60-Month Beta -2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.43
Trade DAWN with:

Options Overview Details

View History
  • Implied Volatility 69.26% ( -1.45%)
  • Historical Volatility 36.23%
  • IV Percentile 12%
  • IV Rank 11.21%
  • IV High 177.94% on 05/31/23
  • IV Low 55.54% on 01/31/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 39
  • Volume Avg (30-Day) 84
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 2,281
  • Open Int (30-Day) 2,395

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.60
  • Number of Estimates 7
  • High Estimate -0.50
  • Low Estimate -0.70
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -13.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.72 +2.12%
on 09/21/23
15.36 -15.43%
on 09/11/23
-0.90 (-6.48%)
since 08/21/23
3-Month
11.14 +16.66%
on 07/07/23
15.36 -15.43%
on 09/11/23
-0.54 (-3.99%)
since 06/21/23
52-Week
10.84 +19.89%
on 04/25/23
25.77 -49.59%
on 01/09/23
-5.31 (-29.02%)
since 09/21/22

Most Recent Stories

More News
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...

KZIA : 1.0000 (-1.05%)
DAWN : 12.99 (-1.07%)
NVS : 102.09 (-1.44%)
Stock Index Futures Muted as Weak China Trade Data Weighs on Sentiment

June S&P 500 futures (ESM23) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.09% this morning as weak trade data from China stoked investor concerns over the strength of global demand....

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
PACW : 7.70 (-3.14%)
WAL : 45.71 (-1.57%)
INTC : 34.65 (-0.12%)
AMD : 96.11 (-4.22%)
COIN : 74.42 (-2.93%)
ITX.E.DX : 35.380 (-1.21%)
YEXT : 6.17 (-0.80%)
GDYN : 11.68 (-2.34%)
VXRT : 0.7111 (-4.09%)
DAWN : 12.99 (-1.07%)
Why Shares of Day One Pharmaceuticals Are Up Monday

The clinical-stage biotech released early trial news regarding its lead therapy candidate.

DAWN : 12.99 (-1.07%)
Stock Index Futures Mixed on Pressure from Rising Bond Yields, Oil Prices Rise After Saudi Output Cuts

June S&P 500 futures (ESM23) are up +0.01%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.25% this morning as market participants digested the U.S. debt ceiling agreement, while U.S. Treasury...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
LULU : 383.90 (-2.04%)
MMM : 97.49 (-1.52%)
AMZN : 129.33 (-4.41%)
VOLCB.S.DX : 44.230 (+0.20%)
MRO : 25.87 (-1.07%)
DVN : 46.41 (-3.07%)
OXY : 62.56 (-2.63%)
DBRG : 16.40 (-5.69%)
RAIN : 0.8500 (+0.59%)
EVAX : 0.7500 (+10.29%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 0.4450 (-5.52%)
DAWN : 12.99 (-1.07%)
SWTX : 24.14 (-1.67%)
VSTM : 9.50 (unch)
KNTE : 1.5000 (-0.66%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 0.4450 (-5.52%)
SWTX : 24.14 (-1.67%)
DAWN : 12.99 (-1.07%)
VSTM : 9.50 (unch)
KNTE : 1.5000 (-0.66%)
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

/PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...

ONC.TO : 2.95 (+4.24%)
GILD : 75.27 (-0.73%)
IMGN : 14.93 (+2.02%)
DAWN : 12.99 (-1.07%)
LEGN : 63.54 (-1.09%)
ONCY : 2.19 (+3.30%)
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END

ONCY : 2.19 (+3.30%)
ONC.TO : 2.95 (+4.24%)
GILD : 75.27 (-0.73%)
IMGN : 14.93 (+2.02%)
DAWN : 12.99 (-1.07%)
LEGN : 63.54 (-1.09%)
Promising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meeting

VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already...

ONCY : 2.19 (+3.30%)
ONC.TO : 2.95 (+4.24%)
GILD : 75.27 (-0.73%)
IMGN : 14.93 (+2.02%)
DAWN : 12.99 (-1.07%)
LEGN : 63.54 (-1.09%)
Stay Away From These 3 Stocks With Bearish Momentum in April

Coupled with fears about an economic downturn, several other headwinds could keep the biotechnology industry under significant pressure. Given this backdrop, fundamentally weak biotech stocks Day One Biopharmaceuticals...

DAWN : 12.99 (-1.07%)
NWBO : 0.9950 (+16.37%)
OCGN : 0.4000 (+1.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 13.58
2nd Resistance Point 13.36
1st Resistance Point 13.17
Last Price 12.99
1st Support Level 12.76
2nd Support Level 12.54
3rd Support Level 12.35

See More

52-Week High 25.77
Fibonacci 61.8% 20.06
Fibonacci 50% 18.30
Fibonacci 38.2% 16.54
Last Price 12.99
52-Week Low 10.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar